SUBSCRIBE
SUBSCRIBE
News   Drug Development

Bristol-Myers Squibb Company: Orencia(R) (Abatacept) Demonstrates Consistent Safety And Effectiveness Over 7 Years

June 12, 2009 | 
1 min read
COPENHAGEN--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of two ORENCIA® (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR) currently being held in Copenhagen, Denmark.
Clinical research Phase 2 Europe
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
March 10, 2026
 · 
3 min read
 · 
Tristan Manalac
Concept World kidney day, handcraft paper blue kidneys and stethoscope on yellow background. Copy space. Banner.
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
March 10, 2026
 · 
2 min read
 · 
Tristan Manalac
Flat 3d isometric business people came from different way but have same target. Business team and target concept.
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Businessman looks at the rugged road
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
March 9, 2026
 · 
2 min read
 · 
Heather McKenzie